2000/569/EC: Commission Decision of 8 September 2000 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (notified under document number C(2000) 2629) (Text with EEA relevance)
Date: 2000-09-08
Institutions: European Commission
Subjects: EU stock, foot-and-mouth disease, research body, vaccine, veterinary legislation

22.9.2000

EN

Official Journal of the European Communities

L 238/61

COMMISSION DECISION

of 8 September 2000

for the purchase by the Community of foot-and-mouth disease antigens and for the formulation,
production, bottling and distribution of vaccines against foot-and-mouth disease

(notified under document number C(2000) 2629)

(Text with EEA relevance)

(2000/569/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European
Community,

Having regard to Council Decision 90/424/EEC of 26 June
1990 on expenditure in the veterinary field (1), as last amended
by Regulation (EC) No 1258/1999 (2), and in particular Article
14 thereof,

Having regard to Council Decision 91/666/EEC of 11
December 1991 establishing Community reserves of foot-and-
mouth disease vaccines (3), as last amended by Decision 1999/
762/EC (4), and in particular Articles 5 and 7 thereof,

(5)

(6)

(7)

Whereas:

Decision

Commission

By
the
Community assisted Turkey to control foot-and-mouth
disease in Thrace by providing vaccine reconstituted
from Community antigen stocks which have to be
replaced.

2000/494/EC (9)

Due to the disease situation, provisions must be made
for the purchase by the Community of additional quant-
ities and strains of foot-and-mouth disease antigens and
their
the formulation, production,
bottling and distribution of vaccines against foot-and-
mouth disease.

storage and for

The measures provided for in this Decision are in
accordance with the opinion of the Standing Veterinary
Committee,

(1)

(2)

(3)

(4)

In conformity with Decision 91/666/EEC, the purchase
of antigens is a part of the Community action to estab-
lish Community reserves of
foot-and-mouth disease
vaccines.

By Commission Decision 93/590/EC of 5 November
1993 for the purchase by the Community of foot-and-
mouth disease antigens within the framework of the
foot-and-
Community action concerning reserves of
mouth disease vaccines (5), as last amended by Decision
2000/112/EC (6), arrangements were made for purchase
of A5, A22 and O1 foot-and-mouth disease antigen.

By Commission Decision 97/348/EC of 23 May 1997
for the purchase by the Community of foot-and-mouth
disease antigens and for the formulation, production,
bottling and distribution of vaccines against foot-and-
mouth disease (7), as last amended by Decision 2000/
112/EC, arrangements were made for purchase of A22
Iraq, C1 and ASIA1 foot-and-mouth disease antigen.

By Commission Decision 2000/77/EC of 17 December
1999 for the purchase by the Community of foot-and-
mouth disease antigens and for the formulation, produc-
tion, bottling and distribution of vaccines against
foot-and-mouth disease (8), arrangements were made for
purchase of certain doses of A Iran 96, A Iran 99, A
Malaysia 97, SAT1, SAT2 (East African and Southern
African strains) and SAT3 foot-and-mouth disease
antigen.

(1) OJ L 224, 18.8.1990, p. 19.
(2) OJ L 160, 26.6.1999, p. 103.
(3) OJ L 368, 31.12.1991, p. 21.
(4) OJ L 301, 24.11.1999, p. 6.
(5) OJ L 280, 13.11.1993, p. 33.
(6) OJ L 33, 8.2.2000, p. 21.
(7) OJ L 148, 6.6.1997, p. 27.
(8) OJ L 30, 4.2.2000, p. 35.

HAS ADOPTED THIS DECISION:

Article 1

The Community shall purchase as soon as possible the

1.
following strains of foot-and-mouth disease antigen:

— A Malaysia 97: 1 500 000 doses,
— SAT1: 1 500 000 doses,
— SAT2 (Southern Africa): 1 500 000 doses,
— SAT2 (East Africa): 1 500 000 doses,
— SAT3: 1 500 000 doses,
— ASIA1: 1 500 000 doses,
— O1 — Manisa: 1 500 000 doses,
— A22 — Iraq: 1 500 000 doses.

2.
The Community shall make arrangements for the storage
of antigen and the formulation, production, bottling and
distribution of
foot-and-mouth disease
against
produced from antigens referred to in paragraph 1.

vaccines

The maximum cost of the measures referred to in para-

3.
graphs 1 and 2 shall be up to EUR 2 650 000.

The action referred to above shall be organised by the

4.
Commission before 31 December 2000.

Article 2

The measures mentioned in Article 1(1) and (2) shall be carried
out by the Commission in cooperation with the supplier desig-
nated by call for tender.

(9) OJ L 199, 5.8.2000, p. 85.

L 238/62

EN

Official Journal of the European Communities

22.9.2000

Article 3

Article 4

This Decision is addressed to the Member States.

To meet the objectives of Articles 1 and 2 the Commis-

1.
sion shall conclude contracts without delay.

Done at Brussels, 8 September 2000.

The Director General of

2.
for
Health and Consumer Protection shall be authorised to sign the
contracts on behalf of the European Commission.

the Directorate General

For the Commission

David BYRNE

Member of the Commission